Read eNews November
![]()
|
![]()
|
Never losing sight of our purpose
At Mestag we truly believe in our values and live by them every day. We’re ambitious about our science and its potential to deliver meaningful therapeutics to the patients that need them most. We believe in a culture of diversity, equality and investing in people to ensure our talented and passionate team members can fulfil their full potential.
Ellipses Pharma is a global drug development company headquartered in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection, the expertise of a Scientific Affairs Group, which comprises more than 300 leading oncologists and an uninterrupted funding flow to minimise the time it takes to advance lead products through clinical trials and reach patients.
Join us for two exciting days that will showcase an exceptional line-up of academic and industry speakers exploring breakthrough stem cell technologies transforming drug discovery and therapeutic development.
Co-hosted by the Babraham Institute and Newcastle University, the Frontiers in Stem Cell Innovation Conference will feature key talks and panel discussion sessions focused on stem cell technologies, disease modelling, and translational research.
This December, we invite our customers and prospective partners to join Catalent for an exclusive open house in Swindon during England’s most enchanting season. As the streets sparkle with festive lights and holiday spirit, you’ll step into a rare opportunity to see how Zydis® ODT, the world’s leading orally disintegrating tablet technology, continues to transform patient-centric drug delivery.
IP education session by Stratagem: IP for Start- ups and SMEs: Leveraging your IP strategy to drive business growth and unlock funding opportunities.
18th November – Glasshouse 4-6pm
For all spin-outs, startups and SMEs. Join Stratagem for an exclusive event at the Cambridge Glasshouse to learn more about how having a well thought out IP strategy which aligns with your business plan and goals will help drive growth and unlock funding opportunities. We will share thoughts about what Investors expect to see in early due diligence.
Partnership with Solve Scientific strengthens international sales as part of ongoing global expansion
BioInfect 2026: Turning Insight into Impact
Join us at BioInfect to connect, collaborate, and shape the next generation of solutions that will preserve the effectiveness of antimicrobial treatments worldwide.
Bionow's BioInfect conference brings together experts from across research, clinical practice, biotech, pharma, and policy to confront this escalating threat through innovation, collaboration, and action.
Key themes include:
By LimestoneGrey, Chartered Tax Advisers specialising in R&D tax relief
Many companies working within the Med-Tech and life sciences sectors are tackling global challenges such as antimicrobial resistance, ageing populations and chronic disease management. Addressing these complex issues often requires research that extends beyond the UK's borders.